Kindling Bio

Kindling Bio is a biotechnology company developing a gene therapy platform designed specifically for childhood cancers.

The platform engineers a biological signal that renders paediatric solid tumours visible to the immune system, enabling immune-mediated destruction across multiple tumour types from a single therapeutic approach.

The company is at pre-clinical stage and is based at the Innovation Gateway within the London Cancer Hub, providing proximity to the Institute of Cancer Research and the Royal Marsden Hospital.